HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,620,007 | +34.7% | 263,675 | +28.0% | 0.02% | +77.8% |
| Q2 2023 | $17,541,735 | -28.3% | 206,034 | -30.3% | 0.01% | -35.7% |
| Q1 2023 | $24,476,954 | +5.8% | 295,794 | +0.5% | 0.01% | +7.7% |
| Q4 2022 | $23,145,987 | +7.9% | 294,291 | +1.6% | 0.01% | 0.0% |
| Q3 2022 | $21,444,000 | +21.8% | 289,663 | +7.3% | 0.01% | +30.0% |
| Q2 2022 | $17,600,000 | +5.4% | 270,016 | +2.2% | 0.01% | +25.0% |
| Q1 2022 | $16,701,000 | +27.6% | 264,170 | +7.1% | 0.01% | +33.3% |
| Q4 2021 | $13,086,000 | -53.3% | 246,739 | -37.8% | 0.01% | -53.8% |
| Q3 2021 | $27,998,000 | -6.4% | 396,622 | -11.6% | 0.01% | -13.3% |
| Q2 2021 | $29,909,000 | +16.2% | 448,809 | +93.5% | 0.02% | +7.1% |
| Q1 2021 | $25,743,000 | +839.5% | 231,891 | +905.3% | 0.01% | +600.0% |
| Q4 2020 | $2,740,000 | +35.4% | 23,066 | -0.5% | 0.00% | +100.0% |
| Q3 2020 | $2,023,000 | -1.0% | 23,187 | +1.6% | 0.00% | -50.0% |
| Q2 2020 | $2,044,000 | -40.4% | 22,819 | -33.7% | 0.00% | -33.3% |
| Q1 2020 | $3,430,000 | -70.8% | 34,413 | -66.4% | 0.00% | -62.5% |
| Q4 2019 | $11,764,000 | +15.2% | 102,392 | +26.4% | 0.01% | +14.3% |
| Q3 2019 | $10,216,000 | -68.1% | 81,005 | -69.6% | 0.01% | -63.2% |
| Q2 2019 | $32,066,000 | -36.2% | 266,493 | -53.6% | 0.02% | -36.7% |
| Q1 2019 | $50,272,000 | -20.4% | 574,698 | -9.0% | 0.03% | -33.3% |
| Q4 2018 | $63,157,000 | -73.7% | 631,279 | -69.8% | 0.04% | -35.7% |
| Q3 2018 | $239,818,000 | +70.0% | 2,093,049 | +33.0% | 0.07% | +75.0% |
| Q2 2018 | $141,103,000 | +139.3% | 1,573,427 | +95.2% | 0.04% | +42.9% |
| Q1 2018 | $58,959,000 | +237.7% | 805,926 | +168.1% | 0.03% | +154.5% |
| Q4 2017 | $17,458,000 | +56.2% | 300,625 | +20.7% | 0.01% | +37.5% |
| Q3 2017 | $11,174,000 | +5.4% | 249,087 | -7.2% | 0.01% | 0.0% |
| Q2 2017 | $10,600,000 | +531.3% | 268,474 | +548.1% | 0.01% | +700.0% |
| Q1 2017 | $1,679,000 | -30.4% | 41,426 | -30.9% | 0.00% | -50.0% |
| Q4 2016 | $2,411,000 | -69.1% | 59,981 | -72.1% | 0.00% | -66.7% |
| Q3 2016 | $7,794,000 | -1.4% | 215,306 | -21.0% | 0.01% | 0.0% |
| Q2 2016 | $7,903,000 | +147.2% | 272,675 | +198.3% | 0.01% | +200.0% |
| Q1 2016 | $3,197,000 | -29.1% | 91,405 | -34.6% | 0.00% | -33.3% |
| Q4 2015 | $4,506,000 | -47.0% | 139,815 | -46.8% | 0.00% | -57.1% |
| Q3 2015 | $8,494,000 | +105.5% | 262,845 | +162.9% | 0.01% | +133.3% |
| Q2 2015 | $4,133,000 | +0.8% | 99,972 | +9.5% | 0.00% | 0.0% |
| Q1 2015 | $4,099,000 | +6.1% | 91,310 | -11.5% | 0.00% | +50.0% |
| Q4 2014 | $3,862,000 | +55.0% | 103,225 | +44.6% | 0.00% | 0.0% |
| Q3 2014 | $2,491,000 | -37.5% | 71,382 | -36.8% | 0.00% | -33.3% |
| Q2 2014 | $3,986,000 | -32.2% | 113,010 | -37.4% | 0.00% | -25.0% |
| Q1 2014 | $5,883,000 | +400.7% | 180,542 | +546.9% | 0.00% | +300.0% |
| Q4 2013 | $1,175,000 | -83.1% | 27,909 | -84.0% | 0.00% | -80.0% |
| Q3 2013 | $6,961,000 | – | 174,595 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |